Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

Systemic cytokine release and on-target/off-tumor toxicity to normal tissues are the main adverse effects limiting the clinical utility of T cell–redirecting therapies. This study was designed to determine how binding affinity for CD3 and tumor target HER2 impact the efficacy and nonclinical safety...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Staflin, Karin, Zuch de Zafra, Christina L., Schutt, Leah K., Clark, Vanessa, Zhong, Fiona, Hristopoulos, Maria, Clark, Robyn, Li, Ji, Mathieu, Mary, Chen, Xiaocheng, Johnston, Jennifer, Low, Justin, Ybarra, Ryan, Slaga, Dionysos, Yang, Jihong, Ovacik, Meric, Dybdal, Noël O., Totpal, Klara, Junttila, Melissa R., Ellerman, Diego, Lee, Genee, Dennis, Mark S., Prell, Rodney, Junttila, Teemu T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7205277/
https://ncbi.nlm.nih.gov/pubmed/32271166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.133757
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados